دورية أكاديمية
أعرض في EDS

Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.

التفاصيل البيبلوغرافية
العنوان: Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
المؤلفون: Sia TY; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America., Manning-Geist BL; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America., Ehmann S; Department of Gynecology & Gynecologic Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany., Lavery JA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America., Luardo C; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America., Praiss A; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America., Iasonos A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America., Sonoda Y; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America., Grisham RN; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Medicine, Weill Cornell Medical College, New York, NY, United States of America., Liu YL; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Medicine, Weill Cornell Medical College, New York, NY, United States of America., Broach V; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America., Zivanovic O; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America., Long Roche K; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America., Gardner GJ; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America., Chi DS; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America. Electronic address: chid@mskcc.org.
المصدر: Gynecologic oncology [Gynecol Oncol] 2023 Sep; Vol. 176, pp. 69-75. Date of Electronic Publication: 2023 Jul 14.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, Academic Press.
مواضيع طبية MeSH: Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/surgery , Ovarian Neoplasms*/pathology, Humans ; Female ; Middle Aged ; Aged ; Carcinoma, Ovarian Epithelial/surgery ; Carcinoma, Ovarian Epithelial/drug therapy ; Cytoreduction Surgical Procedures ; Chemotherapy, Adjuvant ; Neoplasm Recurrence, Local/drug therapy ; Neoadjuvant Therapy ; Neoplasm Staging ; Retrospective Studies
مستخلص: Objectives: To compare outcomes of patients with high-grade epithelial ovarian cancer (EOC) who underwent secondary cytoreduction surgery (SCS) after up-front treatment with neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) versus primary debulking surgery (PDS).
Methods: Patients with high-grade EOC who underwent SCS from 2/1/2004-10/31/2021 were classified by up-front treatment. Clinical and treatment characteristics were compared between cohorts. Progression-free survival (PFS2) and overall survival (OS2) following SCS were compared using a Cox model adjusted for stage, age at SCS, and number of years between end of chemotherapy and SCS.
Results: Of 374 patients, 62 (17%) underwent NACT-IDS and 312 (83%) PDS. Justification for NACT was disease extent (n = 57, 92%), comorbidities (n = 3, 5%), and thromboembolism (n = 2, 3%). The NACT-IDS cohort had a higher median age at SCS (64 years [IQR: 56-70] vs 59 years [IQR: 53-66]; P = .03), higher proportion of stage III/IV disease (100% vs 81%; P < .001), and shorter median interval between end of chemotherapy and SCS (1.5 years [IQR: 1.1-2.3] vs 1.9 years [IQR: 1.3-3.1]; P = .01). Achievement of complete gross resection at SCS did not differ between NACT-IDS and PDS (84% vs 88%; P = .18). PFS2 (HR: 1.19, 95% CI: 0.83-1.71) and OS2 (HR: 0.96, 95% CI: 0.57-1.63) did not vary by primary treatment modality after adjusting for clinically relevant covariates.
Conclusions: Despite more extensive disease at presentation, patients with high-grade EOC who recur after NACT-IDS seem to have similar surgical and survival outcomes after SCS compared to patients who recur after PDS, suggesting that prior NACT-IDS should not preclude SCS.
Competing Interests: Conflict of interest Outside the submitted work, D. Chi reports personal fees from Apyx Medical, Verthermia Inc., Biom ‘Up, and AstraZeneca, as well as recent or current stock/options ownership of Apyx Medical, Verthemia, Intuitive Surgical, Inc., TransEnterix, Inc., Doximity, Moderna, and BioNTech SE. A. Iasonos reports consulting fees from Mylan. J. Lavery discloses salary support from the American Association of Cancer Research Project Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE BPC). Y.L. Liu reports research funding from AstraZeneca, GSK, and Repare Therapeutics. R.N. Grisham reports honoraria from GSK, AstraZeneca, Natera, Springworks, Corcept, MJH, and PER. The other authors do not have potential conflicts of interest to declare.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
References: Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. (PMID: 33028623)
Int J Gynecol Cancer. 2017 May;27(4):675-683. (PMID: 28328580)
N Engl J Med. 2019 Nov 14;381(20):1929-1939. (PMID: 31722153)
N Engl J Med. 2021 Dec 2;385(23):2123-2131. (PMID: 34874631)
Lancet Oncol. 2018 Dec;19(12):1680-1687. (PMID: 30413383)
Gynecol Oncol. 2017 May;145(2):230-235. (PMID: 28285846)
Gynecol Oncol. 2021 Jan;160(1):32-39. (PMID: 33196436)
Ann Surg Oncol. 2006 Dec;13(12):1702-10. (PMID: 17009163)
Gynecol Oncol. 2016 Nov;143(2):236-240. (PMID: 27612977)
Ann Surg Oncol. 2012 Feb;19(2):597-604. (PMID: 21732142)
Gynecol Oncol. 2022 Jun;165(3):453-458. (PMID: 35397918)
Gynecol Oncol. 2018 Jan;148(1):168-173. (PMID: 29128105)
J Clin Oncol. 2016 Nov 10;34(32):3854-3863. (PMID: 27601552)
Gynecol Oncol. 2020 Dec;159(3):687-691. (PMID: 32951891)
J Clin Oncol. 2016 Oct 1;34(28):3460-73. (PMID: 27502591)
J Clin Oncol. 1991 Mar;9(3):389-93. (PMID: 1999708)
JAMA Oncol. 2021 Dec 01;7(12):1782-1790. (PMID: 34591081)
Lancet Oncol. 2021 Apr;22(4):439-449. (PMID: 33705695)
Cancer. 2006 May 1;106(9):1933-9. (PMID: 16572412)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Epithelial ovarian cancer; Interval debulking surgery; Neoadjuvant chemotherapy; Outcomes; Primary debulking surgery; Secondary cytoreduction surgery
تواريخ الأحداث: Date Created: 20230716 Date Completed: 20230904 Latest Revision: 20240902
رمز التحديث: 20240902
مُعرف محوري في PubMed: PMC10530358
DOI: 10.1016/j.ygyno.2023.07.006
PMID: 37454565
قاعدة البيانات: MEDLINE
الوصف
تدمد:1095-6859
DOI:10.1016/j.ygyno.2023.07.006